<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38669">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02129322</url>
  </required_header>
  <id_info>
    <org_study_id>ZYYYMedOncoLT01</org_study_id>
    <nct_id>NCT02129322</nct_id>
  </id_info>
  <brief_title>Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1</brief_title>
  <official_title>Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to investigate the effect of adjuvant therapy by Sorafenib,
      Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver
      transplantation
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to Recurrence (TTR)</measure>
    <time_frame>within five years after liver transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to Recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>within the five years after liver transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Circulative tumor cell (CTC) level change</measure>
    <time_frame>within one year after liver transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Circulative tumor cell</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential :  Sorafenib maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1 and Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_label>S-1 and Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_label>S-1 and Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_label>S-1 and Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hepatocellular carcinoma after liver transplantation

          -  Major organ (heart, lung and brain) function was normal

        Exclusion Criteria:

          -  Any active infectious process

          -  The presence of clinically confirmed extrahepatic metastasis

          -  Postoperative dysfunction of any organ
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijia fang</last_name>
    <role>Principal Investigator</role>
    <affiliation>First affiliated hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weijia fang</last_name>
    <email>weijiafang@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weijiafang fang</last_name>
    </contact>
    <investigator>
      <last_name>Weijia fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>April 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Weijia Fang</investigator_full_name>
    <investigator_title>First affiliated hospital, Zhejiang University</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
